Who are we?

Key figures



Euronext Growth.

Patent Families


All exploitation rights obtained.



France and the United States.

> 35 employees


in R&D.

“VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Founded in 2014, VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.”


VALBIOTIS in a few words

  • Listed on the Stock Exchange on Euronext Growth;
  • Prediabetes – Type 2 Diabetes – Overweight/obesity – NAFL/NASH – Dyslipidemia – Intestinal microbiota;
  • > 35 employees (75% in R&D, over 50% women);
  • 4 patent families filed and all exploitation rights obtained;
  • France: Périgny (17), La Rochelle (17), Riom (63);
  • United States: Boston (Massachusetts);
  • Current markets: France, Europe, United States and Canada.

VALBIOTIS expertise

VALBIOTIS products are specifically designed to reduce the risk factors of certain metabolic diseases in order to delay their onset, or if possible, to prevent at-risk conditions from developing into a disease. Notably, these products are derived from food plants and plant extracts and are subject to rigorous clinical and scientific development. The plants, composed of various active molecules, are the inspiration for this global approach to disease that is based on pleiotropic mechanisms of action. The solutions currently available are not sufficient to stem this worldwide pandemic that is putting the lives of patients at risk as well as burdening healthcare systems. VALBIOTIS believes in a different approach, one that complements current recommendations (healthier food choices, physical activity and sport, etc.).

VALBIOTIS know-how

Metabolic diseases are complex and require a pleiotropic approach. By opting to exclusively use plants in its products, VALBIOTIS focuses its R&D on the multi-target, synergistic effects produced by various biomolecules from the plant totum. VALBIOTIS teams have extensive scientific, clinical and regulatory knowledge, as well as high-level expertise in:

  • New-generation screening techniques;
  • Complete characterization of plant materials;
  • Extraction, purification, fractioning and plant biomolecule
  • Pharmacomodulation processes;
  • Preclinical studies at various levels (molecular, cellular, tissue, in vivo);
  • Design and coordination of clinical trials, operationally implemented by specialized service providers.

R&D – Quality Assurance

To enhance its capacity for and speed of innovation and development:

  • Since its creation, VALBIOTIS has formed numerous partnerships with centers of academic excellence in France and abroad. Its top-ranking partners are La Rochelle University, the CNRS and the University of Clermont-Auvergne. > Find out about our collaborations and partners here 
  • In September 2018, VALBIOTIS internalized a 1,200 m2 platform designed for Discovery and Preclinical Research on metabolic diseases, on its site in Riom (France). > Find out about our R&D center here 
  • The Quality Assurance & Compliance Department at VALBIOTIS is responsible for guaranteeing the strict compliance of R&D activities with the highest applicable standards for health products.


  • 2014

    Creation of the Company at La Rochelle.

  • 2015

    Discovery of active ingredient, "TOTUM-63".

  • 2017

    Initial public offering on the Stock Exchange on the Euronext Growth market.

  • 2017

    Presentation of its Phase I/II clinical results for the active ingredient TOTUM-63, at the American Diabetes Association 77th Scientific Sessions in San Diego, (California, USA).

  • 2018

    Internalization of a technical platform designed for Discovery and Preclinical Research, on its Riom site.

  • 2019

    VALBIOTIS succeeds in the industrial production of VALEDIA® in collaboration with the Pierre Fabre group.

  • 2019

    Positive results from the Phase IIA clinical study of VALEDIA®.